These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32315382)

  • 41. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
    Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Measurable residual disease monitoring using Wilms tumor gene 1 expression in childhood acute myeloid leukemia based on child-specific reference values.
    Løvvik Juul-Dam K; Guldborg Nyvold C; Vålerhaugen H; Zeller B; Lausen B; Hasle H; Beier Ommen H
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27671. PubMed ID: 30900388
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
    Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
    Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels.
    Mullighan CG; Jeha S; Pei D; Payne-Turner D; Coustan-Smith E; Roberts KG; Waanders E; Choi JK; Ma X; Raimondi SC; Fan Y; Yang W; Song G; Yang JJ; Inaba H; Downing JR; Leung WH; Bowman WP; Relling MV; Evans WE; Zhang J; Campana D; Pui CH
    Blood; 2015 Dec; 126(26):2896-9. PubMed ID: 26527677
    [No Abstract]   [Full Text] [Related]  

  • 45. The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia.
    Xue YJ; Wang Y; Jia YP; Zuo YX; Wu J; Lu AD; Zhang LP
    Int J Hematol; 2021 Apr; 113(4):547-555. PubMed ID: 33386596
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
    Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
    J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia.
    Schmiegelow K; Forestier E; Hellebostad M; Heyman M; Kristinsson J; Söderhäll S; Taskinen M;
    Leukemia; 2010 Feb; 24(2):345-54. PubMed ID: 20010622
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Results of therapy in children with acute lymphoblastic leukemia in over 50 years of experience in a single center in Poland.
    Jatczak-Gaca A; Styczynski J; Koltan A; Debski R; Pogorzala M; Wysocki M
    Leuk Lymphoma; 2015 Jul; 56(7):2212-4. PubMed ID: 25547656
    [No Abstract]   [Full Text] [Related]  

  • 51. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
    Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
    Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).
    Schultz KR; Pullen DJ; Sather HN; Shuster JJ; Devidas M; Borowitz MJ; Carroll AJ; Heerema NA; Rubnitz JE; Loh ML; Raetz EA; Winick NJ; Hunger SP; Carroll WL; Gaynon PS; Camitta BM
    Blood; 2007 Feb; 109(3):926-35. PubMed ID: 17003380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-Term Results of the Risk-Stratified Treatment of TCF3-PBX1-Positive Pediatric Acute Lymphoblastic Leukemia in China.
    Wang Y; Xue YJ; Lu AD; Jia YP; Zuo YX; Zhang LP
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e137-e144. PubMed ID: 33221150
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.
    Issa GC; Kantarjian HM; Yin CC; Qiao W; Ravandi F; Thomas D; Short NJ; Sasaki K; Garcia-Manero G; Kadia TM; Cortes JE; Daver N; Borthakur G; Jain N; Konopleva M; Khouri I; Kebriaei P; Champlin RE; Pierce S; O'Brien SM; Jabbour E
    Cancer; 2017 Feb; 123(3):459-467. PubMed ID: 27696391
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
    Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
    Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.
    Pieters R; de Groot-Kruseman H; Van der Velden V; Fiocco M; van den Berg H; de Bont E; Egeler RM; Hoogerbrugge P; Kaspers G; Van der Schoot E; De Haas V; Van Dongen J
    J Clin Oncol; 2016 Aug; 34(22):2591-601. PubMed ID: 27269950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007.
    Kozlowski P; Åström M; Ahlberg L; Bernell P; Hulegårdh E; Hägglund H; Karlsson K; Markuszewska-Kuczymska A; Tomaszewska-Toporska B; Smedmyr B; Hallböök H
    Haematologica; 2012 Sep; 97(9):1414-21. PubMed ID: 22511497
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis.
    Toksvang LN; Grell K; Nersting J; Degn M; Nielsen SN; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Lepik K; Vaitkevičienė G; Griškevičius L; Quist-Paulsen P; Vora A; Moorman AV; Murdy D; Zimmermann M; Möricke A; Bostrom B; Joshi J; Hjalgrim LL; Dalhoff KP; Als-Nielsen B; Schmiegelow K
    Leukemia; 2022 Jan; 36(1):33-41. PubMed ID: 34175901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
    Gandemer V; Pochon C; Oger E; Dalle JH; Michel G; Schmitt C; de Berranger E; Galambrun C; Cavé H; Cayuela JM; Grardel N; Macintyre E; Margueritte G; Méchinaud F; Rorhlich P; Lutz P; Demeocq F; Schneider P; Plantaz D; Poirée M; Bordigoni P
    Br J Haematol; 2014 May; 165(3):392-401. PubMed ID: 24479958
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
    von Stackelberg A; Seeger K; Henze G; Eckert C
    Leukemia; 2004 Oct; 18(10):1727-8; author reply 1728-9. PubMed ID: 15356653
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.